Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

Inclusion Criteria

• •History of diagnosis of prostate cancer after undergoing prostatectomy
• •No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic
• •Eastern Cooperative Oncology Group (ECOG) performance scale 0-2
• •Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable
• •Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry
• •PSA value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion
• •All subjects must have the ability to understand and the willingness to sign a written informed consent